Theratechnologies (NASDAQ:THTX) released its earnings results on Thursday. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.03), MarketWatch Earnings reports. Theratechnologies had a negative net margin of 28.20% and a negative return on equity of 81.13%.
THTX stock opened at $2.27 on Friday. The business has a 50 day moving average price of $2.38 and a 200 day moving average price of $2.23. The stock has a market cap of $174.82 million, a price-to-earnings ratio of -9.46 and a beta of 1.46. Theratechnologies has a fifty-two week low of $1.33 and a fifty-two week high of $4.20. The company has a quick ratio of 1.26, a current ratio of 1.92 and a debt-to-equity ratio of 3.81.
Several equities analysts have recently issued reports on the company. Zacks Investment Research upgraded Theratechnologies from a “sell” rating to a “hold” rating in a research note on Tuesday, September 15th. Royal Bank of Canada reiterated a “hold” rating and issued a $2.00 price objective on shares of Theratechnologies in a research note on Monday, July 20th. Canaccord Genuity reiterated a “buy” rating on shares of Theratechnologies in a research note on Monday, July 13th. Echelon Wealth Partners reiterated a “buy” rating and issued a $11.00 price objective on shares of Theratechnologies in a research note on Wednesday, July 8th. Finally, Mackie reiterated a “buy” rating and issued a $4.50 price objective on shares of Theratechnologies in a research note on Friday. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $6.15.
Theratechnologies Inc, a biopharmaceutical company, markets prescription products in the United States, Europe, and Canada. It offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients.
Recommended Story: Insider Trading
Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.